Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy.

OBJECTIVES To track changes in the V3 env region of HIV-1 quasispecies and determine virus coreceptor use in cell reservoirs of patients on long-term suppressive antiretroviral therapy (ART). PATIENTS AND METHODS Ten patients whose plasma viraemia had been suppressed for a median of 5.5 years were followed for 5 years. The V3 env regions of viruses in peripheral blood mononuclear cells were analysed by ultra-deep sequencing (UDS). HIV-1 tropism was predicted using the geno2pheno 5.75 algorithm and a phenotypic assay. RESULTS The UDS and phenotypic assay data were concordant for predicting HIV-1 tropism. CXCR4-using viruses detected by UDS accounted for 14.7%-76.5% of the virus populations in samples from five patients at enrolment. Five patients harboured pure R5 virus populations and no X4 viruses emerged during the 5 years. The selection pressures estimated by the dN/dS ratio were acting on the V3 region to produce diversification of the quasispecies in CXCR4-infected patients and purification of the quasispecies in R5-infected patients on effective ART. CONCLUSIONS UDS showed that the virus quasispecies in cell reservoirs of patients on long-term suppressive ART continued to evolve. CXCR4-using variants became more diversified. Analysis of the selection pressures on the virus quasispecies could provide a clearer picture of virus persistence in patients on effective ART.

[1]  P. Massip,et al.  Characterization of CXCR4-using HIV-1 during primary infection by ultra-deep pyrosequencing. , 2013, The Journal of antimicrobial chemotherapy.

[2]  J. Mullins,et al.  An Increasing Proportion of Monotypic HIV-1 DNA Sequences during Antiretroviral Treatment Suggests Proliferation of HIV-Infected Cells , 2012, Journal of Virology.

[3]  T. Dallman,et al.  Performance comparison of benchtop high-throughput sequencing platforms , 2012, Nature Biotechnology.

[4]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.

[5]  Ron Milo,et al.  Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy , 2011, Nature.

[6]  Thomas Lengauer,et al.  Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis , 2011, BMC Medical Informatics Decis. Mak..

[7]  V. Calvez,et al.  Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism , 2011, Antimicrobial Agents and Chemotherapy.

[8]  V. Calvez,et al.  Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years , 2011, AIDS.

[9]  J. Izopet,et al.  High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists , 2010 .

[10]  V. Calvez,et al.  Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists. , 2010, The Journal of antimicrobial chemotherapy.

[11]  P. Massip,et al.  Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[12]  G. Angarano,et al.  Co‐receptor switch during HAART is independent of virological success , 2009, Journal of medical virology.

[13]  V. Calvez,et al.  HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART , 2007, AIDS.

[14]  R. Cheynier,et al.  Naïve T-Cell Depletion Related to Infection by X4 Human Immunodeficiency Virus Type 1 in Poor Immunological Responders to Highly Active Antiretroviral Therapy , 2006, Journal of Virology.

[15]  Christophe Pasquier,et al.  R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy , 2005, Journal of acquired immune deficiency syndromes.

[16]  P. Massip,et al.  Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression. , 2002, Virology.

[17]  Ziheng Yang,et al.  Statistical methods for detecting molecular adaptation , 2000, Trends in Ecology & Evolution.

[18]  B. Clotet,et al.  Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. , 1999, Virology.

[19]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[20]  E. Poveda,et al.  High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. , 2010, The Journal of antimicrobial chemotherapy.

[21]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.